- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02462096
A Feasibility Study of the ReLeaf Catheter System (ReLeaf)
A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The ReLeaf catheter system is intended for the creation of tissue leaflets in the deep veins where existing valve structures are no longer healthy and effectively moving blood.
This study aims to treat subjects with a documented history of symptomatic chronic venous insufficiency in whom compression therapy for at least 6 months, combined with superficial venous and/or perforator surgery have failed to obtain clinical improvement.
This clinical trial is designed to evaluate the safety and technical feasibility of the ReLeaf Catheter System in the creation of one or more tissue leaflets in the femoral and/or popliteal vein in subjects with chronic venous insufficiency and who meet the protocol entry criteria.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Auckland, Nieuw-Zeeland
- Auckland City Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- History of symptomatic chronic venous insufficiency subjects, clinical category CEAP 3 or greater.
- History of failed compression therapy (of at least 6 months), combined with superficial venous or perforator surgery.
- Femoral and/or popliteal venous reflux of ≥ 1.0 seconds.
- Deep system reflux with Kistner classification grade 2 or higher.
- 18 years of age or older at the time of consent.
- Willing and able to sign the Ethics Committee (EC) approved informed consent form.
- Willing to comply with follow-up evaluations and protocols.
Exclusion Criteria:
- In the Investigator's opinion, venous outflow obstruction that would inhibit adequate flow away from valve site.
- Obstructive features in the femoral or popliteal vein below the proposed tissue leaflet creation site, which, in the Investigator's opinion, will not allow for sufficient blood flow to the tissue leaflet creation site.
- Deep venous system intervention within 6 months of consent.
- Obstructive features or irregularly small luminal diameter in the femoral vein which, in the opinion of the Investigator, will prohibit access to a tissue leaflet creation site.
- Prior deep vein valve surgical intervention in the ipsilateral limb.
- Ankle arthrodesis with secondary muscle atrophy or severely limited ambulation.
- Limb-threatening circulatory compromise.
- Contraindications to anticoagulation therapy that cannot be medically controlled.
- History of symptomatic pulmonary embolism.
- Acute venous thromboembolism within 3 months of consent.
- Comorbidity risks which, in the opinion of the Investigator, limit longevity or likelihood of complying with protocol follow up.
- General contraindications to surgery or the use of anesthesia.
- Uncontrolled heart failure, or NYHA Class III or IV heart failure.
- Open Cardiac surgery (e.g. ventriculotomy, atriotomy) within the past 6 months of consent (Interventional procedures such as stenting or PTCA do not apply.)
- Chronic Kidney Disease with creatinine level of 2mg/dL or higher.
- Active systemic infection or sepsis.
- Pregnant or lactating (positive pregnancy test, women of childbearing potential must be tested).
- Appropriate vascular access is precluded.
- Subject is enrolled in any other clinical study that, in the opinion of the Investigator, may conflict with this study or compromise study results.
- Subject is considered at high risk for non-compliance with the protocol (e.g., inaccessible for follow-up).
- Other invasive surgical procedure within the last 90 days that in the Investigator's opinion would interfere with the study procedure or results.
- History of stroke within the last 6 months.
- Subject is incarcerated or will be incarcerated during the course of the study.
- Untreated significant superficial venous incompetence
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment
Subject to undergo the ReLeaf study procedure.
|
The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Technical Feasibility
Tijdsspanne: Day 0
|
Technical feasibility will be evaluated as the ability of the ReLeaf Catheter System to access the target site and successfully modify tissue as confirmed by, and in the opinion of, the Investigator.
Successful target site access and confirmed tissue modification will be used as a measure of technical feasibility.
|
Day 0
|
Safety (The number of SAEs directly attributable to the study device will be used as a measure of safety)
Tijdsspanne: Day 30
|
Safety will be evaluated as freedom from serious adverse events directly attributed to the investigational device.
The number of SAEs directly attributable to the study device will be used as a measure of safety.
|
Day 30
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Efficacy
Tijdsspanne: Day 365
|
Subsequent efficacy of the treatment following successful creation of the tissue leaflet(s).
This will be measured through an assessment of tissue leaflet creation and the tissue leaflets ability to impact blood flow over the course of time.
|
Day 365
|
Durability
Tijdsspanne: Day 365
|
Long-term durability of the tissue leaflet(s).
Confirmation of tissue leaflet existence over time will be used to assess the durability of the tissue leaflet.
|
Day 365
|
Long-term Safety (Long-term safety will be measured by freedom from SAEs directly attributable to the study device)
Tijdsspanne: Day 365
|
Further long-term safety data will be collected, analyzed and reported through the end of the study.
Long-term safety will be measured by freedom from SAEs directly attributable to the study device.
|
Day 365
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CLP-0001
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op ReLeaf
-
Phoilex Ltd.Phoenix Medical Spa X Peak HumanWervingAtopische dermatitisCanada
-
Vital 5, LLCIngetrokken